目的 探討甘海胃康膠囊聯(lián)合阿莫西林膠囊和艾司奧美拉唑鎂腸溶片二聯(lián)療法治療消化性潰瘍的臨床療效。方法 選取2021年12月—2023年6月青島市第八人民醫(yī)院收治的204例消化性潰瘍患者，按隨機數(shù)字表法分為對照組和治療組，每組各102例。對照組患者口服阿莫西林膠囊，3粒/次，4次/d，持續(xù)治療14 d，然后停藥；口服艾司奧美拉唑鎂腸溶片，1片/次，4次/d，持續(xù)治療14 d，然后維持劑量1片/次，1次/d，持續(xù)治療2周。治療組在對照組基礎上口服甘海胃康膠囊，6粒/次，3次/d，持續(xù)治療4周。比較兩組的臨床療效、胃鏡療效、幽門螺桿菌轉(zhuǎn)陰率、癥狀緩解時間和血清指標。結果 治療后，治療組的臨床療效總有效率為94.12%，對照組的臨床療效總有效率為85.29%，組間比較差異顯著（P＜0.05）。治療后，治療組的胃鏡療效總有效率為96.08%，對照組的胃鏡療效總有效率為87.25%，組間比較差異顯著（P＜0.05）。治療組患者幽門螺桿菌轉(zhuǎn)陰率96.08%高于對照組的88.24%，組間差異有統(tǒng)計學意義（P＜0.05）。治療組的腹痛、燒心、反酸緩解時間明顯短于對照組，差異有統(tǒng)計學意義（P＜0.05）。治療后，兩組的血清白細胞介素-17（IL-17）、腫瘤壞死因子-α（TNF-α）、內(nèi)皮素（ET）水平均顯著降低（P＜0.05），且治療組血清IL-17、TNF-α、ET水平低于對照組（P＜0.05）。結論 甘海胃康膠囊聯(lián)合阿莫西林膠囊和艾司奧美拉唑鎂腸溶片二聯(lián)療法可提高消化性潰瘍的療效，提高幽門螺桿菌轉(zhuǎn)陰率，促進癥狀緩解，減輕炎癥反應。

Objective To investigate the curative effect of Ganhai Weikang Capsules combined with Amoxicillin Capsules and Esomeprazole Magnesium Enteric-coated Tablets in treatment of peptic ulcers. Methods 204 Patients with peptic ulcers admitted to Qingdao Eighth People’s Hospital from December 2021 to June 2023 were divided into control group and a treatment group using a random number table method, with 102 patients in each group. Patients in the control group were treated with Amoxicillin Capsules, 3 grains/time, 4 times daily, for 14 d, and then stopped. Esomeprazole Magnesium Enteric-coated Tablets were taken orally, 1 tablet/time, 4 times daily, for 14 d, and then the maintenance dose was 1 tablet/time, once daily, for 2 weeks. Patients in the treatment group were given Ganhai Weikang Capsules, 6 grains/time, 3 times/day, for 4 weeks on the basis of control group. The clinical efficacy, gastroscopic efficacy, Helicobacter pylori negative conversion rate, duration of symptom remission, and serum factors of the two groups were compared. Results After treatment, the total effective rate of clinical efficacy in the treatment group (94.12%) was higher than that in the control group (85.29%), and the difference between groups was significant (P < 0.05). After treatment, the total effective rate of gastroscopy efficacy in the treatment group (96.08%) was higher than that of the control group (87.25%), and the difference between groups was significant (P < 0.05). After treatment, H. pylori negative conversion rate in the treatment group (96.08%) was higher than that in the control group (88.24%), and the difference between groups was significant (P < 0.05). After treatment, the remission time of abdominal pain, heartburn, and acid reflux in treatment group was shorer than that in control group (P < 0.05). After treatment, the serum levels of IL-17, TNF-α, and ET were significantly decreased in two groups (P < 0.05), and the serum levels of IL-17, TNF-α, and ET in treatment group was greater than those in the control group (P < 0.05). Conclusion Ganhai Weikang Capsules combined with Amoxicillin Capsules and Esomeprazole Magnesium Enteric-coated Tablets can improve the curative effect of peptic ulcers, increase the H. pylori negative conversion rate, promote the remission of symptoms, and reduce inflammation.

R975

山東省中醫(yī)藥科技項目(M-2023190T);青島市醫(yī)藥科研指導計劃項目(2020-WJZD112)